409 related articles for article (PubMed ID: 32762294)
21. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
[TBL] [Abstract][Full Text] [Related]
22. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
23. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
Ranganathan S; Webber S; Ahuja S; Jaffe R
Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
[TBL] [Abstract][Full Text] [Related]
24. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
26. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
Nagaharu K; Masuya M; Kageyama Y; Yamaguchi T; Ito R; Kawakami K; Ito M; Katayama N
J Med Case Rep; 2018 May; 12(1):151. PubMed ID: 29843820
[TBL] [Abstract][Full Text] [Related]
28. Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Bröckelmann PJ; Sasse S; Engert A
Blood; 2018 Apr; 131(15):1666-1678. PubMed ID: 29500174
[TBL] [Abstract][Full Text] [Related]
29. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
Front Immunol; 2021; 12():756583. PubMed ID: 35095839
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
31. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
32. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
34. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
35. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
Choi Y; Diefenbach CS
Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
[No Abstract] [Full Text] [Related]
37. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient].
Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T
Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
39. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
40. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]